List of articles with "BioArctic"

Eisai Sales Projections

Eisai Sales Projections

Sweden Stockholm Lecanemab Eisai BioArctic
Eisai Sales Projection

Eisai Sales Projection

Sweden Stockholm Eisai Leqembi BioArctic
BioArctic Drug Designation

BioArctic Drug Designation

Sweden Stockholm BioArctic exidavnemab MSA
Exidavnemab Designation

Exidavnemab Designation

Sweden Stockholm BioArctic exidavnemab MSA
Uppsala University Prize

Uppsala University Prize

Sweden BioArctic Alzheimer's Uppsala Uppsala University
Honoring BioArctic's Leaders

Honoring BioArctic's Leaders

Sweden Innovation BioArctic Alzheimer's Uppsala
Lecanemab Not Approved

Lecanemab Not Approved

Australia Lecanemab Eisai BioArctic Canberra
Lecanemab Rejected

Lecanemab Rejected

Australia Eisai BioArctic Alzheimer's Disease Canberra
Lecanemab Update in EU

Lecanemab Update in EU

Sweden Stockholm Lecanemab Eisai BioArctic
Lecanemab Approval Reaffirmed

Lecanemab Approval Reaffirmed

Sweden Stockholm Lecanemab Eisai BioArctic
BioArctic Licensing Deal

BioArctic Licensing Deal

Sweden Stockholm BioArctic Alzheimer's Bristol Myers Squibb
BioArctic and BMS Collaboration

BioArctic and BMS Collaboration

Sweden Stockholm BioArctic Alzheimer’s Bristol Myers Squibb
Leqembi Sales Milestone

Leqembi Sales Milestone

Sweden Stockholm Eisai Leqembi BioArctic
Leqembi® Sales Milestone

Leqembi® Sales Milestone

Sweden Stockholm Eisai Leqembi BioArctic
Lecanemab EU Approval

Lecanemab EU Approval

Sweden Stockholm Lecanemab Eisai BioArctic
Lecanemab Update

Lecanemab Update

Sweden Stockholm Lecanemab Eisai BioArctic
Leqembi Approved for Alzheimer's

Leqembi Approved for Alzheimer's

United States Stockholm Eisai Leqembi BioArctic
FDA Approves Leqembi®

FDA Approves Leqembi®

USA Stockholm Leqembi BioArctic Alzheimer's
Strategic Partnership

Strategic Partnership

Sweden Stockholm BioArctic Bristol Myers Squibb PyroGlu-Aβ
BioArctic-BMS Deal

BioArctic-BMS Deal

Sweden Stockholm BioArctic Bristol Myers Squibb BrainTransporter
Phase 2a Study: Exidavnemab

Phase 2a Study: Exidavnemab

Sweden Stockholm Parkinson's Disease BioArctic exidavnemab
BioArctic's Phase 2a Study

BioArctic's Phase 2a Study

Sweden Stockholm BioArctic Parkinson's exidavnemab
Leqembi® Approved in Mexico

Leqembi® Approved in Mexico

Mexico Mexico City Leqembi BioArctic Alzheimer’s
Leqembi Approved in Mexico

Leqembi Approved in Mexico

Mexico Mexico City Leqembi BioArctic Alzheimer's
Leqembi® Launch in South Korea

Leqembi® Launch in South Korea

South Korea Seoul Eisai Leqembi BioArctic

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.